Lets make this in two parts. Have been doing some due dilligance and wish to flog some questions at you. You said Hextend flew through trials without a hitch and is pending approval. I saw they were in Stage 3, which I felt should put them close, but could find nothing about test results or efficacy or application filing. Doc, I am not a scientist, but I can see considerable potential. On the other hand I watch figures. The company almost gave away 300,000 stock options for prices that were mostly around $7/share, but have ranged up to $42. I didn't care for that. And I see royalties that start closer to 6% than 35% unless it reaches truly whomping sales levels. True, Abbott has paid some cash but not a great deal for what she got. I know nothing of plants being built, but that would be a real plus. Now those observations are simply being realistic, as I see it. But if Hextend is a product that will replace most or all blood transfusions, and it has not had adverse test results, then I think the stock is still well worth the price Can you tell me more about that? As a doctor, you may have heard some reactions, or have news which I have missed. It would be appreciated.
Now, as to stocks I am enthusiastic about:
CYTC - makes Thin Prep for good pap results. FDA approved and breaking into market. It is running $24-28
BTGC - has more than one good drug in the works. $14/share
TXB - also is working on some good ones. $6/share
I think these three are well worth the risk and may give good rewards.
IDPH is a favorite, although I am not as over-weight as in
CTAL - at $13 a real block buster, not because of products (well she does have a polution control system that GE is installing on all her gas turbines) but because she has just plucked a factory from Glaxo's plate, complete with personnel, management, and with a contract to make 800 million in drugs for Glaxo over the next 5 years. Additional factory capacity can be sold to others, and Pfizer is an investor in the company. Went from 20MM to 50MM shares in order to pay for the factory (and used 120MM debt), is not profitable now and may not be next year, so expect to hold 1-2 or more years. One estimate of $.11 next year - maybe.
IGEN - what can I say? A science type fellow I greatly respect was not captivated by their new test system. I thought it sounded pretty revolutionary. I have doubled my money since we went over the stock, and it just now is beginning to really move. She is in suit re. royalty payments with BMG, her mentoring company, which I am convinced she will win, and would be profitable at this point but for the fact that she chose to show all advanced royalties as current liabilities pending litigation. Using electro-chemo-luminessence for testing - besides selling testing machines, just signed a contract with Aguron to do test screening for research candidates. Selling to clinics and hospitals only. I believe more than 3000 testing machines have been sold so far this year, at substantial prices. And I hear the test engine has now been miniturized sufficiently to support a point of care device which has not yet been designed. It will come.
I am heavy in CTAL, IGEN, BTGC and TXB. Also picked up some IDXX and MDCC and GLIA when the market dumped them - I have a profit in each, but I doubt either of those first two will make me rich On the other hand GLIA could be a bomb. . |
